Table 1. Characteristics of Our Sample.
CAMI |
TCIN |
Test | |||
---|---|---|---|---|---|
HC | MDD | HC | MDD | ||
N | 29 | 31 | 21 | 25 | |
Age | 38.28 (12.40) | 40.42 (9.72) | 34.00 (11.63) | 37.76 (13.17) | t=−1.20, p=0.23 |
Sex (F/M) | 17/12 | 21/10 | 13/8 | 15/10 | Chi-square=0.21, p=0.69 |
rs1360780 (CC/T*) | 13/16 | 16/15 | 9/12 | 10/15 | Chi-square=0.06, p=0.85 |
FKBP5 methylation | 60.74 (3.36) | 62.11 (3.69) | 59.36 (3.77) | 60.75 (4.89) | t=−1.74, p=0.08 |
HAMD | 2 (0–7) | 29 (17–45) | 0 (0–5) | 23 (6–31) | U=2797.50, p<0.01 |
BDI | 1 (0–12) | 31 (5–59) | 1 (0–13) | 34 (17–51) | U=2193, p<0.01 |
CTQ total | 30 (25–48) | 40 (25–88) | 28 (25–53) | 36 (25–82) | U=2084, p<0.01 |
Medication type | 9/12/4/3/3 | 4/14/3/2/2 |
Abbreviations: BDI, Beck depression inventory; CAMI, Centre for Advanced Medical Imaging site; CTQ, childhood trauma questionnaire; HAMD, Hamilton scale for depression; HC, healthy controls; MDD, major depressive disorder patients; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; TCIN, Trinity College Institute of Neuroscience site.
For our HC and MDD groups, descriptives of the following measures are given: age, sex, rs1360780 allele status, peripheral mean intron 7 methylation percentage, clinical questionnaire scores, and medication. Parametric variables are shown as mean (SD), non-parametric ones as median (minimum-maximum). Medication is expressed as untreated/SSRI/SNRI/SSRI+SNRI/other (antipsychotic or agomelatine). Statistical tests for comparisons between MDD and HC and their results are also shown.